Related Experiment Video
Updated: Aug 22, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
[Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary
Taishi Hirahara1, Norifumi Kubo, Nobuhiro Ohmura
1Cardiovascular Division, Omiya Medical Center, Jichi Medical School, Saitama.
Insights
Argatroban and heparin show similar effectiveness in preventing acute thrombotic events and restenosis after percutaneous coronary intervention (PCI) for acute myocardial infarction. Argatroban may reduce bleeding complications compared to heparin.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Acute myocardial infarction (AMI) management often involves percutaneous coronary intervention (PCI).
- Adjunctive anticoagulation is crucial after PCI to prevent thrombotic complications.
- Heparin is a standard anticoagulant, but bleeding risks exist.
Purpose of the Study:
- To evaluate argatroban, a direct thrombin inhibitor, as an alternative to heparin for anticoagulation after PCI in AMI patients.
- To compare the efficacy and safety of argatroban versus heparin in preventing re-occlusion and restenosis.
Main Methods:
- A randomized study of 54 AMI patients undergoing PCI within 6 hours of onset.
- Patients received either intravenous argatroban (n=27) or heparin (n=27) for 72 hours.
- Coronary angiography, event monitoring, and bleeding complication assessment were performed.
Main Results:
- No significant differences in acute coronary re-occlusion or major bleeding between groups.
- Minor bleeding complications were significantly lower in the argatroban group (4% vs. 30%, p < 0.05).
- Restenosis and target vessel recanalization rates were similar at 6 months for both treatments.
Conclusions:
- Argatroban is as effective as heparin in preventing acute thrombotic events and restenosis post-PCI in AMI.
- Argatroban may offer a reduced risk of bleeding complications compared to heparin in this patient population.
Objectives:
Argatroban, a selective thrombin inhibitor, is expected to decrease acute coronary re-occlusion and restenosis via direct suppression of thrombin generation after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction. This study evaluated the effect of argatroban compared with heparin as an adjunctive anticoagulation therapy after PCI in patients with acute myocardial infarction.
Methods:
Fifty-four consecutive patients with acute myocardial infarction underwent PCI within 6 hr from the onset and were randomly allocated to receive argatroban (argatroban group: n = 27) or heparin (heparin group: n = 27) after PCI. Each drug was administered intravenously for 72 hr. Coronary angiography was repeated at 1 and 6 months after the onset of acute myocardial infarction. In-hospital cardiac events, bleeding complications, and long-term outcome were surveyed.
Results:
Baseline clinical and angiographic variables were similar in the two groups. Acute coronary re-occlusion and major hemorrhagic complications did not occur in either group. Minor bleeding complications, such as hematoma of the puncture sites, occurred significantly less frequently in the argatroban group than in the heparin group (4% vs 30%, p < 0.05). After 6 months, there were no significant differences in restenosis rate and target vessel recanalization rate between the two groups. Subgroup analyses revealed no significant differences in restenosis rate between patients treated with only balloon angioplasty and stent implantation.
Conclusions:
Argatroban provides similar prevention of acute thrombotic events and restenosis compared with heparin. However, argatroban might reduce bleeding complications in patients with acute myocardial infarction after PCI.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care